ClinicalTrials.gg
RecruitingNCT04342910Updated Jan 20, 2026

Study to Evaluate the Efficacy and Safety of Camrelizumab and Apatinib in Patients With GC/GEJC

A Phase 3 interventional study of camrelizumab and Apatinib Mesylate in Gastric Cancer, sponsored by Jiangsu HengRui Medicine Co., Ltd.. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-01-20.

Sponsored by Jiangsu HengRui Medicine Co., Ltd. · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Apr 2026, 7 months ago, but the record still lists the study as recruiting.
  • Started Sep 2020; still recruiting 6 years 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
550
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 33 studies testing camrelizumab in Stomach Neoplasms — 8 open to participants now, 11 under way, 2 of them phase 3. camrelizumab · Stomach Neoplasms.

Planned enrollment
2nd of 33
550 · median 46
Started
2020
with 10 others
Phase 3
3 of 33
2 open now
Primary completion
2026-04
later than 8 of 10 live
Registered
13th of 33
by date
Lead sponsor
3 of 33
Jiangsu HengRui Medicine Co., Ltd.

Among the 33 studies testing camrelizumab in Stomach Neoplasms, this one is the 2nd largest by planned enrollment, is one of 11 that started in 2020, is one of 3 in phase 3, reaches primary completion later than 8 of the 10 other live ones, and was the 13th registered.

Stomach Neoplasms

3,403 studies on the registry are indexed under Stomach Neoplasms; 995 are open to participants now.

Browse Stomach Neoplasms studies →

Open to participants now

8 of the 33 studies testing camrelizumab in Stomach Neoplasms are open now, in 1 country. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 8 open studies →

Where they have run

About camrelizumab

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 704 Stomach Neoplasms studies recruiting now, 376 (53%) set no upper age limit and 194 (28%) stop at 75 or younger; 28 take children under 18; 69 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 33 studies testing camrelizumab in Stomach Neoplasms, or all of them as a file.
02

Study summary

This is a study for participants with advanced gastric or gastroesophageal junction adenocarcinoma who have had tumor progression after first-line platinum-contained therapy. The primary study hypotheses are that camrelizumab (SHR-1210) combined with apatinib prolongs overall survival (OS) for participants with tumors that show positive programmed cell death ligand 1 (PD-L1) expression.

03

Conditions studied

  • Gastric Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. - or cytologically-confirmed diagnosis of gastric or gastroesophageal junction adenocarcinoma.
  2. Confirmed or locally advanced, unresectable disease.
  3. Progression on or after prior therapy containing any platinum/fluoropyrimidine or platinum/taxane doublet.
  4. Willing to provide tumor tissue for biomarker analysis.
  5. Human epidermal growth factor receptor 2 (/neu) status known and participants with HER2/neu positive tumors show documentation of previous treatment containing trastuzumab.
  6. performance status of 0 to 1.
  7. of more than 12 weeks.
  8. Signing the forms.
  9. Adequate bone marrow, liver and renal function.

Exclusion criteria

Exclusion Criteria:

  1. Squamous cell or undifferentiated gastric cancer.
  2. Known active central nervous system (CNS) and/or carcinomatous meningitis.
  3. Subjects with an active, known or suspected disease. Patients with type I diabetes who are receiving a stable dose of insulin, hypothyroidism who only needs hormone replacement therapy, and skin diseases (such as eczema, vitiligo, or psoriasis) that do not require systemic treatment and do not have acute deterioration within 1 year before the screening period, are allowed.
  4. cardiovascular and cerebrovascular diseases.
  5. Subjects with high blood pressure who cannot be controlled well with antihypertensive drugs.
  6. Previous digestive tract bleeding history within 3 months or evident gastrointestinal bleeding tendency.
  7. Arterial / venous thrombosis events, such as cerebrovascular accidents (including , cerebral hemorrhage, cerebral infarction), deep vein thrombosis, and pulmonary embolism, occurred within the first 6 months of randomization.
  8. Subjects who have previously received / PD-L1 monoclonal antibody, anti-CTLA-4 monoclonal antibody, and VEGFR small molecule inhibitor therapy.
  9. Prior systemic chemotherapy, radiotherapy and surgery within 4 weeks before the study drug administration, or any unresolved AEs > (CTCAE) Grade 1.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
550 participants (estimated)

Study arms

  • Experimental
    camrelizumab (SHR-1210) combined with apatinib

    Participants will receive camrelizumab on Day 1 and Day 15 of each 28-day cycle and apatinib mg/day up to 2 years.

    Drug: camrelizumab · Drug: Apatinib Mesylate

  • Active comparator
    Paclitaxel or Irinotecan

    Participants receive paclitaxel on Days 1, 8, and 15 of each 28-day cycle, or irinotecan on Days 1 and 15 of each 28-day cycle.

    Drug: Paclitaxel · Drug: Irinotecan

Interventions

  • 200 mg intravenous (IV) camrelizumab on Day 1 and Day 15 of each 28-day cycle.

    Also known as: SHR-1210

  • 250 mg qd

  • 80 mg/m\^2 administered as IV infusion on Days 1, 8, and 15 of each 28-day cycle.

  • 180 mg/m\^2 administered as IV infusion on Days 1, and 15 of each 28-day cycle.

06

What researchers measure

Primary outcomes

  1. Overall Survival (OS) in PD-L1 Positive Participants.

    OS was defined as the time from randomization to death due to any cause.

    Time frame: Up to 27 months

Secondary outcomes

  1. Overall Survival (OS) in All Participants.

    OS was defined as the time from randomization to death due to any cause.

    Time frame: Up to 27 months

  2. Progression-free Survival (PFS) According to RECIST 1.1 base on investigator assessment in All Participants or in PD-L1 Positive Participants.

    PFS was defined as the time from randomization to the first documented disease progression per RECIST 1.1 based on investigator assessment, or death due to any cause, whichever occurs first.

    Time frame: Up to 27 months

  3. Time to Tumor Progression (TTP) According to RECIST 1.1 based on investigator assessment in All Participants or in PD-L1 Positive Participants.

    TTP was defined as the time from randomization to the first documented disease progression per RECIST 1.1 based on investigator assessment in All Participants.

    Time frame: Up to 27 months

  4. Time to Failure (TTF) in All Participants or in PD-L1 Positive Participants

    TTF was defined as the time from randomization to treatment discontinuation caused by any reason.

    Time frame: Up to 27 months

  5. Objective Response Rate (ORR) According to RECIST 1.1 based on investigator assessment in All Participants or in PD-L1 Positive Participants.

    ORR was defined as the percentage of the participants in the analysis population who had a confirmed CR or PR according to RECIST 1.1 based on investigator assessment.

    Time frame: Up to 27 months

  6. Duration of Response (DOR) According to RECIST 1.1 Based on investigator assessment in All Participants or in PD-L1 Positive Participants.

    DOR was defined as the time from first documented evidence of CR or PR until disease progression or death due to any cause, whichever occurs first.

    Time frame: Up to 27 months

  7. Disease Control Rate (DCR) According to RECIST 1.1 based on investigator assessment in All Participants or in PD-L1 Positive Participants.

    DCR was defined as the percentage of the participants in the analysis population who had a confirmed CR or PR or SD according to RECIST 1.1 based on investigator assessment.

    Time frame: Up to 27 months

  8. Time to Response (TTR) According to RECIST 1.1 based on investigator assessment in All Participants or in PD-L1 Positive Participants.

    TTR was defined as the time from randomization to the first documented evidence of CR or PR.

    Time frame: Up to 27 months

  9. The incidence and severity of adverse events (AEs) and serious adverse events (SAEs) as assessed by CTCAE v4.03.

    The incidence and severity of adverse events (AEs) and serious adverse events (SAEs) as assessed by CTCAE v4.03.

    Time frame: Up to 27 months

  10. Proportion of dose suspension, dose reduction or dose discontinuation caused by treatment-related toxicities.

    Proportion of dose suspension, dose reduction or dose discontinuation caused by treatment-related toxicities.

    Time frame: Up to 27 months

  11. Proportion of anti-camrelizumab antibody (ADA) and neutralizing antibody (Nab) formed during the study from baseline

    Proportion of anti-camrelizumab antibody (ADA) and neutralizing antibody (Nab) formed during the study from baseline

    Time frame: Up to 27 months

  12. Serum concentration of camrelizumab

    Serum concentration of camrelizumab

    Time frame: Up to 27 months

  13. Plasma concentration of apatinib

    plasma concentration of apatinib

    Time frame: Up to 27 months

07

Study locations

1 of 1 sites recruiting
  • Affiliated Hospital, Academy of Military Medical Sciences
    Beijing, China
    Recruiting
    • Jianming Xu, PhD · Contact
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2020 (actual). Primary completion is estimated for Apr 2026, 66 months after the start.

Of 45 industry-sponsored phase 3 interventional studies under Stomach Neoplasms, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 32 and three quarters within 55. This study's planned 66 months is above that.

Counting every sponsor, half of 118 studies reached it within 52 months; a quarter within 39 and three quarters within 96.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 9, 2020
First posted
Apr 13, 2020
StartActual
Sep 21, 2020
Primary completionEst.
Apr 1, 2026
CompletionEst.
Sep 1, 2026
Last update
Jan 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 20, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04342910
Responsible party
Sponsor
First posted
Apr 13, 2020
Start date
Sep 21, 2020
Primary completion
Apr 1, 2026 (estimated)
Completion
Sep 1, 2026 (estimated)
Last update
Jan 20, 2026

Study contacts

Quanren Wang, Ph.D
Contact
wangquanren@hrglobe.cn
+862161053363
Jianming Xu, Ph.D
principal investigator · Affiliated Hospital, Academy of Military Medical Sciences

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Camrelizumab · Apatinib

Start the discussion